The stock has been in a pronounced downtrend over the last six months, with the price falling approximately 65% from around $56 in early October 2025 to a recent close of $19.78. The 52-week range is wide, from a low of $3.92 to a high of $161.00, indicating extreme volatility, with the current price trading near the lower end of this spectrum. Over the last three months, the stock has declined by 27.15%, significantly underperforming the S&P 500, which was down 4.63% over the same period. However, in the most recent month, the stock has shown a gain of 4.22%, which is a positive relative strength of 9.47% compared to the market's 5.25% decline, suggesting potential short-term stabilization or a minor rebound from oversold conditions.

Revenue for the latest quarter (Q1 2026) was $2.29 million, representing a significant year-over-year growth of 90.95%. However, the company reported a substantial net loss of -$5.20 billion for the quarter, translating to an EPS of -$15.98, which severely impacts profitability metrics. The company's financial health shows a debt-to-equity ratio of 0, indicating no debt on the balance sheet, and a very high current ratio of 51.5, suggesting strong short-term liquidity. However, trailing twelve-month free cash flow is deeply negative at -$233.83 million, highlighting significant cash burn from operations and capital expenditures.